Login / Signup

Detection of gluten immunogenic peptides and the Celiac Disease Adherence Test to monitor gluten-free diet: a pilot study.

Gry Irene SkodjeFrida van MegenMarianne StendahlChristine HenriksenKnut Erik Aslaksen LundinMarit Bragelien Veierød
Published in: European journal of clinical nutrition (2022)
Gluten immunogenic peptides (GIP) in feces and/or urine have recently been proposed as a sensitive and specific marker to detect ongoing gluten intake. Here, we compared GIP with the Celiac Disease Adherence Test (CDAT), a simple validated self-administered questionnaire that measures adherence to gluten-free diet (GFD). Of 70 subjects (59 women), six were classified as non-adherent by fecal GIP (mean 0.23 µg/g, standard deviation 0.08, range 0.082-0.319), including five classified as non-adherent by CDAT. GFD adherence was significantly higher by GIP than CDAT (p < 0.001). Fecal GIP may be useful as a biomarker for ongoing gluten intake that is not possible to detect with current clinical methods to assess GFD adherence, and may play a role in the management of persistent gastrointestinal symptoms in celiac disease.
Keyphrases
  • celiac disease
  • glycemic control
  • physical activity
  • type diabetes
  • pregnant women
  • cross sectional
  • metabolic syndrome
  • weight gain
  • body mass index
  • label free